Prometheus Biosciences is a biotechnology company developing a precision medicine approach to the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting with inflammatory bowel disease. Co. utilizes its proprietary precision medicine platform, Prometheus360, which includes a gastrointestinal bioinformatics database and sample biobank, to identify therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, Co. is developing companion diagnostic tests designed to identify patients more likely to respond to our therapeutic candidates. The RXDX average annual return since 2021 is shown above.
The Average Annual Return on the RXDX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RXDX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RXDX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|